Anticancer therapy induced cardiotoxicity: review of the literature.
Innovative anticancer strategies have contributed to an improved survival of patients suffering from malignancies, and in some cases, have turned cancer into a chronic disease. Therefore, the early and particularly late onsets of adverse cardiovascular effects of systemic anticancer treatments are of increasing interest. Among a rapidly increasing variety of anticancer drugs, the anthracyclines and the monoclonal antibody, trastuzumab, are the agents with a well-known cardiotoxicity. The diagnostic work-up, the cardiotoxic risk of anthracyclines and trastuzumab, and additionally, cardiotoxicity as a risk factor of a multimodal therapeutic approach in breast cancer patients is discussed in this study.
Geiger
Sandra
S
Medical Department III, Haematology and Oncology, Ludwig-Maximilians University of Munich, Campus Grosshadern, Munich, Germany.
Lange
Veronika
V
Suhl
Patricia
P
Heinemann
Volker
V
Stemmler
Hans-Joachim
HJ
D000818:Animals; D018943:Anthracyclines / Q000009:adverse effects / Q000633:toxicity; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000633:toxicity; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000633:toxicity; D009320:Atrial Natriuretic Factor / Q000097:blood; D054715:Cardiotoxins / Q000009:adverse effects* / Q000633:toxicity; D006321:Heart / Q000187:drug effects*; D006333:Heart Failure / Q000097:blood / Q000175:diagnosis; D006335:Heart Injuries / Q000139:chemically induced / Q000453:epidemiology; D006801:Humans; D011832:Radiation Injuries / Q000453:epidemiology; D011878:Radiotherapy / Q000009:adverse effects; D000068878:Trastuzumab
D018943:Anthracyclines; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D054715:Cardiotoxins; D009320:Atrial Natriuretic Factor; D000068878:Trastuzumab